Abstract
The potential of somatic cell therapies from human embryonic stem cells (hESCs) as alternatives to traditional drug-based remedies for treating some of mankind's most debilitating diseases has resulted in the need to translate rapidly proof-of-principle and basic research into clinical application. Consequently, researchers and regulatory bodies are now facing one of the major obstacles of the field: the efficient and reproducible generation of clinical-grade cells suitable for producing therapeutic cell types to administer to patients in phase-I and phase-II clinical trials.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Cell Culture Techniques* / standards
-
Cell Differentiation
-
Cell Proliferation
-
Cell Separation* / standards
-
Embryo Research* / legislation & jurisprudence
-
Embryonic Stem Cells / physiology
-
Embryonic Stem Cells / transplantation*
-
Government Regulation
-
Human Experimentation* / legislation & jurisprudence
-
Human Experimentation* / standards
-
Humans
-
Quality Control
-
Regenerative Medicine / legislation & jurisprudence
-
Regenerative Medicine / methods*
-
Regenerative Medicine / standards
-
Stem Cell Transplantation* / legislation & jurisprudence
-
Stem Cell Transplantation* / standards
-
United Kingdom